BEVERLY HILLS, Calif., June 25, 2012 (GLOBE NEWSWIRE) -- OXIS International, Inc. (OXIS) (OXI.PA) today announced the international commercial launch of its proprietary, clinically proven, joint health product, ErgoFlex(TM) (www.ergoflexbest.com). A study published last month in the peer reviewed journal of Preventive Medicine clearly demonstrated ErgoFlex's ability to reduce pain, increase range of motion and significantly improve the quality of life from people who suffer from joint pain. <\/p>\n
Unlike any other antioxidant available to consumers, our catalyst ingredient in ErgoFlex, EGT, is referred to as the \"intelligent antioxidant\" because it is the only antioxidant having a dedicated transport mechanism in the body to deliver it through the cell membrane and even into the mitochondria, the energy producing area of the cell. Additionally, when other powerful antioxidants are also present, the body preferentially utilizes ergothioneine. <\/p>\n
OXIS holds the exclusive patent to manufacture EGT, which has received full GRAS (safety) approval. OXIS' marketing partner, engage:BDR, has been developing a comprehensive, full digital advertising campaign for a pipeline of OXIS' proprietary EGT(TM) dietary supplements and anti-aging personal care products. <\/p>\n
\"This is a major step forward in demonstrating the company's focus of delivering our proprietary EGT(TM) based products direct to consumers. Our partners at engage:BDR have an outstanding track record executing on direct-to-consumer product campaigns and ability to deliver our product message to a much-targeted audience that will make for a very successful launch. I am anticipating significant revenue ramp-up with ErgoFlex with additional products to follow soon,\" said David Saloff, Chairman and CEO of OXIS International. <\/p>\n
\"OXIS International's team has demonstrated tremendous expertise in product development, one such being the EGT product line which we're extremely excited to deliver to the market,\" said Ted Dhanik, president, engage:BDR. <\/p>\n
About OXIS International, Inc. <\/p>\n
OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress\/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, including EGT(TM) (99% pure L-ergothioneine), known as the intelligent antioxidant. <\/p>\n
About engage:BDR <\/p>\n
engage:BDR provides advertisers cutting-edge marketing solutions, advanced technology and custom programming by integrating display, video and branded entertainment into a single network. Whether it's driving qualified traffic and leads or building awareness and engagement, engage:BDR is committed to providing innovative solutions to reach consumers and deliver the highest quality results to their partners. Headquartered in Los Angeles, engage:BDR attracts a list of top name partners and customers including Ask.com, Bose, CBS Interactive, eHarmony, Live Nation, Sony Pictures among others. <\/p>\n<\/p>\n
Read the original here: BEVERLY HILLS, Calif., June 25, 2012 (GLOBE NEWSWIRE) -- OXIS International, Inc. (OXIS) (OXI.PA) today announced the international commercial launch of its proprietary, clinically proven, joint health product, ErgoFlex(TM) (www.ergoflexbest.com). Continue reading
\nOXIS Announces the International Launch of Online Sales for ErgoFlex(TM)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"